Octreotide

2 Drugs classified under this active ingredient

Antigrowth Hormone. Octreotide 0.05, 0.1, 0.5 mg/ml.
AMPS (sol. for inject./infus.): 5 x 0.05, 0.1,
0.5 mg/ml.
Dosage must be ajust. individ. See lit.
Prevent. complicats. follow. pancreat.
surg., symptomat. control and reduct. GH
and IGF-1 plasma levels in pts. with
ecromegaly who are inadequate.
controlled by surg., radiother. or dopamine agonist. Acromegalic unfit or unwilling to undergo surg., or in the interim period until
radiother. becomes fully affect. Relief of
sympts. associated with gastroenteropancreat.
endocrin tumors: carcinoid tumors with features of the carcinoid syndr.; VIPomas; glucagonomas; gastrinomas / Zollinger- Ellison syndr. usually in conjunct. with select
H2-antagonist ther; insulinomas, for preop.
control of hypoglycem., for maint. ther.; GRFomas. Not antitumor ther., not
curative in these pts. Emergency manage.
Bleed gastro-esoph. varices second. to
cirrhos. In comb. specific ther. such as
sclerother.
C/I: Hypersens.

Somatostatin Analog. Octreotide 10, 20, 30 mg.
VIALS: 1. (2 vehicle amp + 1 inject set).
By deep intraglut. inject. See lit.
Acromeg. in pts. adequat. controlled on
standard dose Sandostatin S.C. in whom
surg. radiother., or dopamine-agonist tmt.
inapprop. or ineffect., in latency period bef.
radiother. becomes fully effect. Endocrine
gastro-entro-pancreat. (GEP) tumors,
carcinoid tumors.
VIALS: 1. (1 prefilled syringe + 2 needles)
x 20 mg, 30 mg. By deep intraglut.
inject. See lit.
Acromeg. in pts. adequat. controlled on
standard dose Sandostatin S.C. in whom
surg. radiother. inapprop. or ineffect., in
latency period bef. radiother. becomes
fully effect. Endocrine gastro-entropancreat.
(GEP) tumors, carcinoid
tumors.